enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. AstraZeneca bets on new cancer treatments with $2 billion ...

    www.aol.com/news/astrazeneca-bets-cancer...

    The drugmaker will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday. AstraZeneca bets on new cancer treatments with $2 billion Fusion ...

  3. Will Fusion Pharmaceuticals Inc. (FUSN) Report Negative Q2 ...

    www.aol.com/news/fusion-pharmaceuticals-inc-fusn...

    Fusion Pharmaceuticals Inc. (FUSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  4. Even if it's not a huge purchase, we think it was good to see that Steven Gannon, the Independent Director of Fusion... Insider Buying: The Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Independent ...

  5. J. Michael Pearson - Wikipedia

    en.wikipedia.org/wiki/J._Michael_Pearson

    J. Michael Pearson (born 1959) is a Canadian American [1] pharmaceutical company executive. He is the former chairman and CEO of Valeant Pharmaceuticals International [2] [3] after being ousted in the aftermath of a report on pharmaceutical pricing published by Citron Research in April 2016.

  6. Portal:Current events - Wikipedia

    en.wikipedia.org/wiki/Portal:Current_events

    The United States Federal Drug Administration approves Vertex Pharmaceuticals' new Journavx drug, a non-opioid analgesic used to treat acute pain and potentially eliminate the risks of opioid addiction and overdose. Politics and elections

  7. AstraZeneca - Wikipedia

    en.wikipedia.org/wiki/AstraZeneca

    That same month, the firm also announced the acquisition of Fusion Pharmaceuticals Inc for $2 billion in cash. [ 100 ] In July 2024, National Institute for Health and Care Excellence (Nice) blocked the National Health Service (NHS) from providing Enhertu , an innovative treatment for advanced HER2-low breast cancer, due to AstraZeneca and ...

  8. Fusion Pharmaceuticals (NASDAQ:FUSN) Is In A Good ... - AOL

    www.aol.com/news/fusion-pharmaceuticals-nasdaq...

    For premium support please call: 800-290-4726 more ways to reach us

  9. ALK inhibitor - Wikipedia

    en.wikipedia.org/wiki/ALK_inhibitor

    Ariad's and Takeda's brigatinib (also an inhibitor of mutated EGFR) was the latest second-generation inhibitor and was approved in April 2017 by the US FDA for ALK-positive NSCLC. [14] It is very similar to alectinib in efficacy, while being active against some resistant mutations such as the common G1202R mutation that provides resistance to ...